GH1 and neoplasm: Higher growth hormone levels (34.5 ± 7.3 ng/mL vs. 18.4 ± 6.9 ng/mL, p < 0.05), tumor size (13.4 ± 3.6 cm3 vs. 6.3 ± 4.2 cm3, p < 0.05), and tumor recurrence (25.8% vs. 9.7%) were shown in the high-PTTG1 group compared to the low-PTTG1 group (Table 2).